Answers are grounded in this paper and cite their sources.
Significant gaps remain in the health risk assessment methodologies for the PFOS (perfluorooctanesulfonic acid) alternative 6:2 Cl-PFESA (6:2 chlorinated polyfluoroalkyl ether sulfonate, F-53B), which has been widely recognized as the alternative to PFOS in China. To address this research gap, our study integrated multidimensional techniques to mechanistically construct an Adverse Outcome Pathway (AOP) for F-53B-induced ovarian cancer progression. Our findings demonstrated that exposure to environmentally relevant concentrations of F-53B significantly enhanced the migratory and invasive capabilities of ovarian cancer cells. Within the AOP framework of F-53B-induced hybrid epithelial-mesenchymal transition (EMT) and enhanced tumor stemness, the upregulation of C5aR1─triggered by ERα acting as a noncanonical receptor of F-53B─constitutes the molecular initiating event (MIE). Following this MIE, the recruitment of β-arrestin1 and Src was induced, leading to the assembly of a C5aR1/β-arrestin1/Src signaling complex. This complex facilitated the binding of β-arrestin1 to β-catenin and drove the nuclear translocation of β-catenin, ultimately activating hybrid EMT and stemness of tumor cells. Administration of the C5aR1 inhibitor PMX205 effectively abrogated subsequent key events (KEs) caused by F-53B exposure. Through in vitro and in vivo validation, our study established an AOP framework that provides a novel perspective for evaluating the potential risk of PFAS substitutes in promoting cancer progression.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: